Therapeutic Vaccines Market: 2016 - 2022

  • ID: 4429392
  • Report
  • 110 pages
  • Zion Market Research
1 of 3

The report covers forecast and analysis for the therapeutic vaccines market on a global and regional level. The study provides historic data from 2014 along with a forecast for 2017 to 2022 based revenue (USD Billion). The study includes drivers and restraints for the therapeutic vaccines market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the therapeutic vaccines market on a global level.

In order to give the users of this report a comprehensive view on the therapeutic vaccines market, we have to include competitive landscape and analysis of Porter's Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein product segments and technology segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new therapy launch, agreements, partnerships, collaborations & joint ventures, research& development, therapy and regional expansion of major participants involved in the market on the global and regional basis.

The study provides a decisive view on the therapeutic vaccines market by segmenting the market based on therapy, technology, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2022. Based on the product the market is segmented into addiction vaccines, autoimmune disease vaccines, infectious disease vaccines and neurological disease vaccines. The technology segment is classified into autologous vaccines and allogeneic vaccines. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for therapeutic vaccines based on the individual segment in all the regions and countries.

Some of the key players in therapeutic vaccines market include Valeant Pharmaceuticals, BioVex, Inc., Inovio Pharmaceuticals, Inc., Immunocellular Therapeutics, Ltd., Agenus Inc., GlaxoSmithKline plc., Pfizer Inc., Novartis AG, Argos Therapeutics, Bavarian Nordic, Transgene, Galena Biopharma and Vaccinogen, Inc. among others.

This report segments the global therapeutic vaccines market as follows:

Global Therapeutic Vaccines Market: Product Segment Analysis

  • Addiction Vaccines
  • Autoimmune Disease Vaccines
  • Infectious Disease Vaccines
  • Neurological Disease Vaccines

Global Therapeutic Vaccines Market: Technology Segment Analysis

  • Autologous vaccines
  • Allogeneic vaccines

Global Therapeutic Vaccines Market: Regional Segment Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa
READ MORE
Note: Product cover images may vary from those shown
2 of 3
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global therapeutic vaccines market, 2016 – 2022 (USD Billion)
    • 2.2. Global therapeutic vaccines market : Snapshot
  • Chapter 3. Therapeutic Vaccines– Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global therapeutic vaccines market drivers: Impact analysis
      • 3.2.2. Growing incidences of chronic diseases
      • 3.2.3. Technological advancements
    • 3.3. Market restraints
      • 3.3.1. Global therapeutic vaccines market restraints: Impact analysis
      • 3.3.2. High treatment cost
    • 3.4. Opportunities
      • 3.4.1. Increasing focus on personalized medicine
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by product segment
      • 3.6.2. Market attractiveness analysis, by technology segment
      • 3.6.3. Market attractiveness analysis, by regional segment
  • Chapter 4. Global Therapeutic Vaccines Market – Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global therapeutic vaccines market: company market share, 2015
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Therapy Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Therapy and Regional Expansion
  • Chapter 5. Global Therapeutic Vaccines Market – Product Segment Analysis
    • 5.1. Global therapeutic vaccines market: Product overview
      • 5.1.1. Global therapeutic vaccines market revenue share, by product, 2014 and 2022
    • 5.2. Addiction Vaccines
      • 5.2.1. Global addiction vaccines market , 2014 – 2022(USD Billion)
    • 5.3. Autoimmune Disease Vaccines
      • 5.3.1. Global autoimmune disease vaccines market , 2014 – 2022(USD Billion)
    • 5.4. Infectious Disease Vaccines
      • 5.4.1. Global infectious disease vaccines market , 2014 – 2022(USD Billion)
    • 5.5. Neurological Disease Vaccines
      • 5.5.1. Global neurological disease vaccines market , 2014 – 2022(USD Billion)
  • Chapter 6. Global Therapeutic vaccines Market – Technology Segment Analysis
    • 6.1. Global therapeutic vaccines market: Technology overview
      • 6.1.1. Global therapeutic vaccines market revenue share, by technology, 2016 and 2022
    • 6.2. Autologous vaccines
      • 6.2.1. Global therapeutic vaccines market for autologous vaccines, 2014 – 2022 (USD Billion)
    • 6.3. Allogeneic Vaccines
      • 6.3.1. Global therapeutic vaccines market for allogeneic vaccines, 2014 – 2022(USD Billion)
  • Chapter 7. Global Therapeutic vaccines Market – Regional Segment Analysis
    • 7.1. Global therapeutic vaccines market: Regional overview
      • 7.1.1. Global therapeutic vaccines market revenue share, by region, 2016 and 2022
    • 7.2. North America
      • 7.2.1. North America therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
      • 7.2.2. North America therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
        • 7.2.3.2. U.S. therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
      • 7.3.2. Europe therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
      • 7.3.3. Germany
        • 7.3.3.1. Germany therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
        • 7.3.3.2. Germany therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
      • 7.3.4. France
        • 7.3.4.1. France therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
        • 7.3.4.2. France therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
      • 7.3.5. UK
        • 7.3.5.1. UK therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
        • 7.3.5.2. UK therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific therapeutic vaccines market revenue, by product, 2014 – 2022, (USD Billion)
      • 7.4.2. Asia Pacific therapeutic vaccines market revenue, by technology, 2014 – 2022, (USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
        • 7.4.3.2. China therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
        • 7.4.4.2. Japan therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
        • 7.4.5.2. India therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
      • 7.5.2. Latin America therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil therapeutic vaccines market revenue, by product, 2014 – 2022(USD Billion)
        • 7.5.3.2. Brazil therapeutic vaccines market revenue, by technology, 2014 – 2022 (USD Billion)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa therapeutic vaccines market revenue, by product, 2014 – 2022 (USD Billion)
      • 7.6.2. Middle East and Africa therapeutic vaccines market revenue, by technology, 2014 – 2022(USD Billion)
  • Chapter 8. Company Profile
    • 8.1. Valeant Pharmaceuticals
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Agenus Inc.
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. GlaxoSmithKline plc.
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Immunocellular Therapeutics, Ltd.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Pfizer Inc.
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Novartis AG
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Argos Therapeutics
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Bavarian Nordic
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Galena Biopharma
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Therapy portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Transgene
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Therapy portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments
    • 8.11. Vaccinogen, Inc.
      • 8.11.1. Overview
      • 8.11.2. Financials
      • 8.11.3. Therapy portfolio
      • 8.11.4. Business strategy
      • 8.11.5. Recent developments
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll